Also trades as: KSPHF (OTC) · $vol 0M
4547.T JPX
Kissei Pharmaceutical Co., Ltd.
1W: -5.0%
1M: -9.7%
3M: -9.5%
YTD: -20.6%
1Y: -13.8%
3Y: +34.5%
5Y: +90.7%
¥3,685.00 ($23.32)
-15.00 (-0.41%)
Weekly Expected Move ±2.9%
¥3488
¥3594
¥3700
¥3806
¥3912
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Balance Sheet Trends
Total Assets
$275.1B
+12.7% ▲
5Y CAGR: +0.5%
Total Liabilities
$43.5B
+28.3% ▲
5Y CAGR: -2.3%
Shareholders Equity
$230.1B
+10.1% ▲
5Y CAGR: +1.0%
Cash & Investments
$54.4B
+11.9% ▲
5Y CAGR: +4.1%
Total Debt
$1.2B
-21.7% ▼
5Y CAGR: -6.4%
Net Debt
-$27.8B
-18.0% ▼
Assets vs Liabilities & Equity
Year-over-Year Growth
View Full Balance Sheet
| Line Item | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
| — Assets — | |||||
| Cash | $30.0B | $25.9B | $22.9B | $25.2B | $29.1B |
| Short-Term Investments | $23.1B | $23.7B | $23.0B | $23.5B | $25.4B |
| Cash & ST Investments | $53.2B | $49.6B | $45.9B | $48.7B | $54.4B |
| Net Receivables | $22.8B | $22.8B | $28.7B | $29.7B | $31.6B |
| Inventory | $19.0B | $22.8B | $26.3B | $25.0B | $25.5B |
| Other Current Assets | $4.4B | $5.4B | $3.6B | $3.7B | $3.4B |
| Total Current Assets | $99.3B | $100.6B | $104.6B | $107.0B | $115.0B |
| Property, Plant & Equip. | $24.1B | $24.6B | $24.9B | $27.1B | $28.1B |
| Goodwill & Intangibles | $1.6B | $1.5B | $2.0B | $1.9B | $2.0B |
| Long-Term Investments | $96.6B | $51.1B | $106.4B | $84.9B | $104.3B |
| Other Non-Current Assets | $15.9B | $43.0B | $22.6B | $22.7B | $25.2B |
| Total Non-Current Assets | $138.7B | $120.6B | $156.4B | $137.1B | $160.1B |
| Total Assets | $238.1B | $221.2B | $260.9B | $244.1B | $275.1B |
| — Liabilities — | |||||
| Accounts Payable | $4.1B | $4.6B | $4.9B | $4.6B | $6.7B |
| Short-Term Debt | $1.6B | $1.5B | $1.3B | $1.4B | $1.2B |
| Deferred Revenue | $8.1B | $4.1B | $1.5B | $1.0B | $846M |
| Other Current Liabilities | -$269M | $2.7B | $5.7B | $5.9B | $5.6B |
| Total Current Liabilities | $18.7B | $15.0B | $17.7B | $16.6B | $21.7B |
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 |
| Other Non-Current Liab. | $906M | $1.0B | $944M | $705M | $832M |
| Total Non-Current Liabilities | $17.2B | $11.4B | $22.1B | $17.4B | $21.9B |
| Total Liabilities | $35.9B | $26.4B | $39.8B | $33.9B | $43.5B |
| — Equity — | |||||
| Common Stock | $24.4B | $24.4B | $24.4B | $24.4B | $24.4B |
| Retained Earnings | $118.2B | $125.6B | $127.3B | $131.5B | $136.3B |
| Accumulated OCI | $47.5B | $32.7B | $57.3B | $43.5B | $60.8B |
| Total Stockholders Equity | $201.4B | $193.9B | $220.0B | $209.0B | $230.1B |
| Total Liabilities & Equity | $238.1B | $221.2B | $260.9B | $244.1B | $275.1B |
| — Key Metrics — | |||||
| Total Debt | $1.6B | $1.5B | $1.3B | $1.6B | $1.2B |
| Net Debt | -$28.4B | -$24.4B | -$21.6B | -$23.6B | -$27.8B |
| Total Investments | $119.8B | $74.8B | $129.4B | $108.4B | $129.6B |